Impact of computed tomography and 18F-deoxyglucose coincidence detection emission tomography image fusion for optimization of conformal radiotherapy in non-small-cell lung cancer.

PURPOSE To report a retrospective study concerning the impact of fused 18F-fluoro-deoxy-D-glucose (FDG)-hybrid positron emission tomography (PET) and CT images on three-dimensional conformal radiotherapy planning for patients with non-small-cell lung cancer. METHODS AND MATERIALS A total of 101 patients consecutively treated for Stage I-III non-small-cell lung cancer were studied. Each patient underwent CT and FDG-hybrid PET for simulation treatment in the same treatment position. Images were coregistered using five fiducial markers. Target volume delineation was initially performed on the CT images, and the corresponding FDG-PET data were subsequently used as an overlay to the CT data to define the target volume. RESULTS 18F-fluoro-deoxy-D-glucose-PET identified previously undetected distant metastatic disease in 8 patients, making them ineligible for curative conformal radiotherapy (1 patient presented with some positive uptake corresponding to concomitant pulmonary tuberculosis). Another patient was ineligible for curative treatment because the fused PET-CT images demonstrated excessively extensive intrathoracic disease. The gross tumor volume (GTV) was decreased by CT-PET image fusion in 21 patients (23%) and was increased in 24 patients (26%). The GTV reduction was > or = 25% in 7 patients because CT-PET image fusion reduced the pulmonary GTV in 6 patients (3 patients with atelectasis) and the mediastinal nodal GTV in 1 patient. The GTV increase was > or = 25% in 14 patients owing to an increase in the pulmonary GTV in 11 patients (4 patients with atelectasis) and detection of occult mediastinal lymph node involvement in 3 patients. Of 81 patients receiving a total dose of > or = 60 Gy at the International Commission on Radiation Units and Measurements point, after CT-PET image fusion, the percentage of total lung volume receiving >20 Gy increased in 15 cases and decreased in 22. The percentage of total heart volume receiving >36 Gy increased in 8 patients and decreased in 14. The spinal cord volume receiving at least 45 Gy (2 patients) decreased. Multivariate analysis showed that tumor with atelectasis was the single independent factor that resulted in a significant effect on the modification of the size of the GTV by FDG-PET: tumor with atelectasis (with vs. without atelectasis, p = 0.0001). CONCLUSION The results of our study have confirmed that integrated hybrid PET/CT in the treatment position and coregistered images have an impact on treatment planning and management of non-small-cell lung cancer. However, FDG images using dedicated PET scanners and respiration-gated acquisition protocols could improve the PET-CT image coregistration. Furthermore, the impact on treatment outcome remains to be demonstrated.

[1]  Sadek Nehmeh,et al.  Does registration of PET and planning CT images decrease interobserver and intraobserver variation in delineating tumor volumes for non-small-cell lung cancer? , 2005, International journal of radiation oncology, biology, physics.

[2]  S. Hain,et al.  FDG-PET as a "metabolic biopsy" tool in non-lung lesions with indeterminate biopsy , 2001, European Journal of Nuclear Medicine and Molecular Imaging.

[3]  E. Yorke,et al.  Does the registration of FDG-PET and planning CT images decrease inter- and intra-observer variation in delineating tumor volumes for non-small cell lung cancer (NSCLC) , 2004 .

[4]  J. Matthews,et al.  Early mortality after radical radiotherapy for non-small-cell lung cancer: comparison of PET-staged and conventionally staged cohorts treated at a large tertiary referral center. , 2002, International journal of radiation oncology, biology, physics.

[5]  Curtis B Caldwell,et al.  The impact of (18)FDG-PET on target and critical organs in CT-based treatment planning of patients with poorly defined non-small-cell lung carcinoma: a prospective study. , 2002, International journal of radiation oncology, biology, physics.

[6]  D. Owens,et al.  Test Performance of Positron Emission Tomography and Computed Tomography for Mediastinal Staging in Patients with NonSmall-Cell Lung Cancer , 2003, Annals of Internal Medicine.

[7]  Suresh Senan,et al.  Literature-based recommendations for treatment planning and execution in high-dose radiotherapy for lung cancer. , 2004, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[8]  J C Rosenwald,et al.  Evaluation of microscopic tumor extension in non-small-cell lung cancer for three-dimensional conformal radiotherapy planning. , 2000, International journal of radiation oncology, biology, physics.

[9]  S U Berlangieri,et al.  The contribution of 18F-fluoro-2-deoxy-glucose positron emission tomographic imaging to radiotherapy planning in lung cancer. , 1998, Lung cancer.

[10]  E. Harman,et al.  FDG SPECT in patients with lung masses. , 1999, Chest.

[11]  J. Jett,et al.  Development of multifield three-dimensional conformal radiotherapy of lung cancer using a total lung dose/volume histogram , 1995 .

[12]  C B Caldwell,et al.  Observer variation in contouring gross tumor volume in patients with poorly defined non-small-cell lung tumors on CT: the impact of 18FDG-hybrid PET fusion. , 2001, International journal of radiation oncology, biology, physics.

[13]  V J Lowe,et al.  Lung tumor growth correlates with glucose metabolism measured by fluoride-18 fluorodeoxyglucose positron emission tomography. , 1995, The Annals of thoracic surgery.

[14]  J C Rosenwald,et al.  Conformal radiotherapy (CRT) planning for lung cancer: analysis of intrathoracic organ motion during extreme phases of breathing. , 2001, International journal of radiation oncology, biology, physics.

[15]  J A Purdy,et al.  Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC) , 1999, International journal of radiation oncology, biology, physics.

[16]  V Kalff,et al.  F‐18 fluorodeoxyglucose positron emission tomography staging in radical radiotherapy candidates with nonsmall cell lung carcinoma , 2001, Cancer.

[17]  Cyrill Burger,et al.  PET-CT image co-registration in the thorax: influence of respiration , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[18]  E. Gunel,et al.  Probability of malignancy in solitary pulmonary nodules using fluorine-18-FDG and PET. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[19]  H. Groen,et al.  Preoperative staging of non-small-cell lung cancer with positron-emission tomography. , 2000, The New England journal of medicine.

[20]  Cyrill Burger,et al.  Radiation treatment planning with an integrated positron emission and computer tomography (PET/CT): a feasibility study. , 2003, International journal of radiation oncology, biology, physics.

[21]  B. Weynand,et al.  PET-FDG scan enhances but does not replace preoperative surgical staging in non-small cell lung carcinoma. , 2001, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[22]  D Delbeke,et al.  Prospective investigation of positron emission tomography in lung nodules. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  J Bogaert,et al.  Lymph node staging in non-small-cell lung cancer with FDG-PET scan: a prospective study on 690 lymph node stations from 68 patients. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  K Schnabel,et al.  18F-deoxyglucose positron emission tomography (FDG-PET) for the planning of radiotherapy in lung cancer: high impact in patients with atelectasis. , 1999, International journal of radiation oncology, biology, physics.

[25]  Gerald J. Kutcher,et al.  The impact of 18F-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in patients with non-small cell lung cancer , 2000 .

[26]  John L. Humm,et al.  Radiotherapy treatment planning for patients with non-small cell lung cancer using positron emission tomography (PET). , 2002, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[27]  Jacqueline C. Brunetti,et al.  4D PET/CT - early observations on integration and impact in radiation therapy planning for lung cancer , 2004 .

[28]  J C Rosenwald,et al.  CT and (18)F-deoxyglucose (FDG) image fusion for optimization of conformal radiotherapy of lung cancers. , 2001, International journal of radiation oncology, biology, physics.

[29]  J. Albes,et al.  Improvement of non-small-cell lung cancer staging by means of positron emission tomography. , 1999, The Thoracic and cardiovascular surgeon.

[30]  Bernard Dubray,et al.  Conformal radiotherapy for lung cancer: different delineation of the gross tumor volume (GTV) by radiologists and radiation oncologists. , 2002, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[31]  M. Satouchi,et al.  Dosimetric predictors of radiation esophagitis in patients treated for non-small-cell lung cancer with carboplatin/paclitaxel/radiotherapy. , 2001, International journal of radiation oncology, biology, physics.

[32]  A. Dowlati,et al.  Evaluation of the solitary pulmonary nodule by positron emission tomography imaging. , 1996, The European respiratory journal.

[33]  P C Goodman,et al.  Staging non-small cell lung cancer with whole-body PET. , 1999, Radiology.

[34]  Jeffrey D Bradley,et al.  Molecular (functional) imaging for radiotherapy applications: an RTOG symposium. , 2003, International journal of radiation oncology, biology, physics.

[35]  A. Guhlmann,et al.  FDG positron emission tomography in the diagnosis of peripheral pulmonary focal lesions. , 2000, The Thoracic and cardiovascular surgeon.

[36]  Sasa Mutic,et al.  Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer. , 2004, International journal of radiation oncology, biology, physics.

[37]  James A. Purdy,et al.  3-D Conformal Radiotherapy for Lung Cancer , 1996 .

[38]  M. O'Doherty,et al.  Evaluation of fluorine-18-fluorodeoxyglucose whole body positron emission tomography imaging in the staging of lung cancer. , 1999, The Annals of thoracic surgery.

[39]  R. Hustinx,et al.  Whole-body 18FDG positron emission tomography in the staging of non-small cell lung cancer. , 1997, The European respiratory journal.

[40]  M. Goitein,et al.  Tolerance of normal tissue to therapeutic irradiation. , 1991, International journal of radiation oncology, biology, physics.

[41]  R. Coleman,et al.  Focal pulmonary abnormalities: evaluation with F-18 fluorodeoxyglucose PET scanning. , 1993, Radiology.

[42]  Arjan Bel,et al.  Definition of gross tumor volume in lung cancer: inter-observer variability. , 2002, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[43]  G. V. von Schulthess,et al.  Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. , 2003, The New England journal of medicine.

[44]  T G Turkington,et al.  Multimodality nuclear medicine imaging in three-dimensional radiation treatment planning for lung cancer: challenges and prospects. , 1999, Lung cancer.